The current popularity of multiple-dose insulin regimens aimed at strict glycemic control has underscored the importance of maintaining fasting glucose levels in diabetic patients as close to normal as possible. Failure to achieve this goal often results in the perpetuation of hyperglycemia for the remainder of the day or attempts at corrective measures with supplemental doses of insulin that often miss the mark. The therapeutic obstacle imposed by fasting hyperglycemia is best appreciated in the context of its pathogenesis, namely, hepatic glucose overproduction. Once the liver's glucose-synthesizing capacity has been activated in the morning, it is not readily suppressed by injections of insulin or the rise in glucose concentration that accompanies meals (1, 2) . The inappropriate persistence of endogenous glucose release during breakfast further accelerates glucose delivery to the bloodstream, well beyond the capacity of peripheral disposal mechanisms that are known to be impaired in diabetic patients (3) . The net effect is a further expansion of the extracellular glucose pool that requires either many hours to reverse or large doses of insulin to overcome peripheral insulin resistance. Because these depot injections are determined empirically and cause prolonged elevations in circulating insulin, such attempts at compensation may lead to hypoglycemia later in the day.
The recognition that successful management of diabetes begins with control of fasting glucose levels (and its associated glucose overproduction) has focused attention on the factors responsible for hyperglycemia in the morning. The most obvious cause, inadequate insulin delivery overnight, remains the foremost diagnostic consideration. However, it has become popular to invoke the Somogyi or dawn phenomenon, often without clinical documentation that either has a contributory role. This may be partly attributed to the difficulty in obtaining glucose measurements during the night but may also reflect the tendency of physicians and patients alike to focus on more exotic diagnostic alternatives. In this issue of Diabetes Care, Havlin and Cryer (4) have, by monitoring glucose levels at 0300 h, evaluated how often fasting hyperglycemia (at 0700 h) is preceded by low or normal glucose levels, a clinical situation that would be adversely affected by a decision to increase insulin dosage. Their data suggest that the significance of the Somogyi and dawn phenomena may be overrated. The reasons for the discrepancy between the findings reported here and the clinical observations and laboratory data used to support the opposite conclusion deserve further scrutiny.
The concept that marked hyperglycemia in diabetic patients may follow insulin-induced hypoglycemia was originally proposed by Somogyi (5) on the basis of careful analyses of urine glucose records from a handful of "the most severe, unmanageable diabetics on the roster of our clinic." This phenomenon, which bears his name, rapidly gained acceptance among clinicians, perhaps because patients classified as "brittle" often responded, just as Somogyi predicted, to a reduction in insulin dose. In retrospect, many of the cases of excessive insulin treatment were probably the result of the faulty monitoring techniques available at that time. Insulin dosage adjustments based on measurements of glycosuria commonly led to inappropriate therapeutic decisions.
Somogyi postulated that posthypoglycemic hyperglycemia in insulin-dependent diabetes mellitus (IDDM) results from the stimulation of endogenous counterregulatory mechanisms. However, recent studies suggest this supposition may be incorrect. It is now appreciated that patients with IDDM display a decreased (rather than increased) capacity to overcome insulin-induced hypoglycemia. This defect in glucose counterregulation is largely mediated by the failure of these patients to appropriately release glucagon in response to hypoglycemia (6); the problem may be further complicated by a blunted epinephrine response (7) . The net result is a sluggish and diminished rebound stimulation of hepatic glucose production that limits and delays recovery from hypoglycemia (8, 9) .
How can such data be reconciled with the concept of the Somogyi phenomenon? A partial explanation may be derived from studies by Gale et al. (10) . They identified a subgroup of IDDM patients with nocturnal hypoglycemia who developed rebound fasting hyperglycemia. Those patients were distinguished by their lower insulin levels, implying that insulin withdrawal was required to allow activated counter' regulatory mechanisms to be expressed. This hypothesis derives support from experimental data showing that when plasma insulin levels are kept constant at levels as low as 20-25 |xU/ ml by low-dose intravenous insulin infusion, posthypoglycemic hyperglycemia does not occur (8, 11) . Thus, the persistent effects of evening injections of long-acting insulin and a diminished counterregulatory response may combine to explain Havlin and Cryer's failure to observe a marked glucose increment after nocturnal hypoglycemia. The patients at greatest risk for nocturnal hypoglycemia, namely, those receiving intensified insulin treatment regimens, are especially likely to follow this course. Recent data suggest that strict glycemic control causes a further deterioration in glucose counterregulation by increasing hepatic sensitivity to insulin and by decreasing counterregulatory hormone responses to hypoglycemia (11, 12) . On the other hand, the current observations may not apply to all patients with IDDM. For example, children, who were not included in this report, have a much greater epinephrine response to hypoglycemia (13) as well as more pronounced insulin resistance and growth hormone hypersecretion (14) • Note also that the current data were obtained in a controlled environment in the hospital. In "real life," patients often ingest much more carbohydrate to overcome hypoglycemic symptoms than they are allowed to do on a metabolic ward. Such behavior is rarely recorded in patients' logs and is commonly overlooked. Overeating may therefore be the most common phenomenon explaining the clinical impression that "hypoglycemia begets hyperglycemia."
The idea that plasma glucose may rise in the morning (with the sun) in patients with IDDM independent of nocturnal hypoglycemia has only recently become widely appreciated. In 1981, Schmidt et al. (15) coined the term dawn phenomenon to describe this entity. Similar, but much smaller, glucose changes have also been reported in patients with non-insulin-dependent diabetes mellitus (NIDDM) (16) . Although the mechanisms responsible for the dawn phenomenon are not definitively established, recent data suggest that a delayed effect of sleep-associated growth hormone spikes on hepatic glucose production is of primary importance (17) . An additional factor may be delayed recovery from shortacting insulin administered in the evening. Insulin's stimulatory effects on glucose metabolism persist for many hours after insulin levels have been restored to baseline (18) . Regardless of the mechanisms, the clinical result is a decrease in basal insulin requirements between 0200 and 0400 h, followed by an increase between 0400 and 0800 h.
Why has it taken so long to recognize the dawn phenomenon? It is possible that with past inadequate insulin regimens, other factors had a much more powerful influence on fasting glucose levels than the more subtle effects produced by the dawn phenomenon. For example, when hepatic glucose production is stimulated during the night because of inadequate single-dose insulin treatment, it is unlikely that the nocturnal rise in growth hormone will have much additional effect. This is particularly true because growth hormone levels are already increased in such patients. Furthermore, when poorly controlled patients are hyperglycemic during the night because of dietary indiscretions, increased renal glucose excretion may offset the rise in glucose production due to the dawn phenomenon. Therefore, the dawn phenomenon would be most prominent in optimally treated patients showing near-normal glucose levels and rates of glucose production. Consequently, it is not surprising that Havlin and Cryer only detected the dawn phenomenon in diabetics with 0300 h glucose levels of <100 mg/dl.
What accounts for Havlin and Cryer's failure to see a pronounced dawn-associated glucose increment in their diabetic patients when many other studies show dramatic overnight glucose elevations? A partial explanation may be the heavy reliance on the Biostator in many earlier studies (16, 17, 19) . It has been reported by some (20, 21) , but not all (22) , workers that insulin is inactivated when infused with a Biostator over extended periods. If this is true, the magnitude of the dawn phenomenon may have been overestimated. Recently, it has been suggested that marked fasting hyperglycemia (> 150 mg/dl) may still occur when insulin is infused continuously with a syringe pump (21) . However, in that study, plasma glucose began rising after midnight, implying that minimal basal insulin requirements had not been fully replaced.
Whereas the magnitude of the dawn phenomenon may be attenuated by maintaining more adequate levels of insulin overnight (4, 23, 24) , modest dawn-associated glucose elevations (20-50 mg/dl) are common during intensified insulin therapy and interfere with efforts to achieve strict glycemic control. Indeed, this may explain why the midmorning blood glucose value is usually the highest of the day. The Havlin and Cryer data, on the other hand, carry a warning not to feel overly secure with normal prebreakfast glucose values. The latter were commonly observed in patients with 0300 h glucose readings <50 mg/dl. Thus, the Somogyi phenomenon, with or without the dawn phenomenon, may be more likely to mask nocturnal hypoglycemia than cause pronounced fasting hyperglycemia.
Several simple solutions to this dilemma come to mind. Most important, patients attempting to achieve strict glycemic control need to monitor 0300 h glucose levels more regularly. Moving intermediate-acting insulin injections from supper to bedtime minimizes the risk of insulin levels peaking at the time of lowest insulin requirements. Finally, it may sometimes be helpful to switch patients from human to animal insulin. The earlier peak insulin levels that occur with human preparations may cause problems when injection schedules are moved to bedtime. Of course, these solutions are simple only for the nondiabetic clinician, who does not have to set the alarm clock at 0300 h or take extra injections or fingersticks. 
